The new NICE guideline on thyroid cancer (NG10150)  is currently in development.  All the project information is on the NICE Website, here. 

The Thyroid Trust are stakeholders in the development of this NICE guideline.  You can send us any comments you would like to ask us to make on your behalf, during the various development stages. 

Patients and carers were invited to apply to sit on the committee as lay members. 

Our chair of Trustees, Judith Taylor, is leading on our submissions to NICE and has provided the following update (on 20th June 2020): 

Latest News on the thyroid cancer guideline

Work has started on the new NICE guideline Thyroid cancer: assessment and management. 

The scoping workshop was held in London on 19 November and I attended this along with several other stakeholders including surgeons, clinicians, researchers, and representatives of other patient organisations. The draft scope went out for consultation just before Christmas and we submitted our comments on 17 January. Unfortunately, when the revised scope was published, our comments were missing … NICE agreed to review our comments and adjust the scope if appropriate, but the pandemic intervened and NICE attention shifted to COVID-19 and it has therefore taken longer than expected to carry out the review.

The NICE reviewers have now considered all of our comments and as a consequence have made some changes to the published scope – specifically they have included active surveillance (also known as ‘watchful waiting’) as one of the initial ‘treatments’ for thyroid cancer. We are delighted by this positive outcome, because patients who are offered active surveillance initially if their thyroid tumour is small may be confused and even stressed when they are not immediately offered treatment. We are also pleased to note that post-surgical hypocalcaemia and voice issues which were flagged up by ourselves and several other stakeholders are included. NICE has now circulated the stakeholders to alert them to the changes with links to the revised scope and stakeholder comments, and included an apology to the Thyroid Trust for overlooking our submission.

Here are the links to the revised scope and to the stakeholder comments, including the TTT comments and responses:
https://www.nice.org.uk/guidance/gid-ng10150/documents/final-scope-2  
https://www.nice.org.uk/guidance/gid-ng10150/documents/consultation-comments-and-responses

The new guideline is due to be published on 4 April 2022.

If anyone is interested in helping to review the draft guideline when this is sent out for consultation please drop me a line.

Judith Taylor
Chair, Board of Trustees
The Thyroid Trust
chair@thyroidtrust.org ​

NICE Guideline NG145

Dr Kristien Boelart MD, PhD, MRCP gave a talk and answered questions on the new NICE guideline on thyroid disease assessment and management (NG145), which was published in November 2019, at our Information Event in London on 25th January 2020 and was one of several speakers at a British Thyroid Foundation event which went into more detail in February 2020 and you can watch videos of some of the talks.  Find out more.​